NASDAQ: HBIO

Harvard Bioscience, Inc.

Healthcare | Medical - Instruments & Supplies

No licensed closing price on file for HBIO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Harvard Bioscience, Inc. (NASDAQ: HBIO) is a medical instruments and supplies company. Figures from SEC EDGAR; updated 2026-10-20 12:07 UTC.

What Harvard Bioscience, Inc. does

Harvard Bioscience develops and sells technologies, products, and services that enable advances in life science research, drug discovery, and preclinical testing. The company, which traces its origins to 1901, serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and contract research organizations globally through operations in the United States, Europe, and China.

Summarized from Harvard Bioscience, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-02
Return on equity	-412.84%
Debt/equity	4.94

Revenue, margins & earnings

Net income
Taxes & interest
Operating expenses
Cost of revenue
Net loss year

Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-12

Most recent filed transactions — June 2026:

2026-06-12DirectorAward16,556—
2026-06-11DirectorAward16,556—
2026-06-11DirectorAward16,556—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

WEBER CAPITAL MANAGEMENT LLC /ADV310,861$1.91M-2.9%
Meros Investment Management, LP182,992$1.13M+54.4%
VANGUARD CAPITAL MANAGEMENT LLC169,625$1.04M+3.9%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-03-10Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-08-13Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-07-17Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
seekingalpha.com2026-08-11
Harvard Bioscience beats top-line and bottom-line estimates; gives Q3 and raises FY2026 outlook
Seeking Alpha Markets2026-08-11POS
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Harvard Bioscience, Inc. do?

Harvard Bioscience develops and sells technologies, products, and services that enable advances in life science research, drug discovery, and preclinical testing.

When did HBIO last file with the SEC?

Harvard Bioscience, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:07 UTC. This page is also available as JSON at /api/data?ticker=HBIO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for HBIO and 5,000+ tickers.

Create a free account — keep HBIO

For your agent

GET /api/data?ticker=HBIO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt